Peng J, Liang T, Chen C, et al. - Researchers conducted this retrospective study to characterize the surgical procedures, outcomes, and complications of a novel technique of subretinal injection of ranibizumab (SRR). Thirty-seven eyes of 26 consecutive children with vascularly active total retinal detachments in 1 or both eyes treated with SRR as primary treatment were included between September 2012 and September 2018. All eyes included received subretinal injection of ranibizumab (0.25 mg/ 0.025 ml). In this very limited research, the authors demonstrated that SRR is effective and promising in advanced vascularly active pediatric vasoproliferative disorders with total retinal detachments, although more rigorous controlled trials would be required to validate its safety and efficacy.